Last reviewed · How we verify
Inactivated adjuvanted Influenza Vaccine
Inactivated adjuvanted Influenza Vaccine is a Vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Influenza prevention in adults.
This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, with an adjuvant to enhance the immune response.
This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, with an adjuvant to enhance the immune response. Used for Influenza prevention in adults.
At a glance
| Generic name | Inactivated adjuvanted Influenza Vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Inactivated adjuvanted influenza vaccines contain killed influenza virus particles combined with an immunological adjuvant that amplifies the body's adaptive immune response. The adjuvant enhances antibody production and cellular immunity against the vaccine antigens, providing improved protection compared to non-adjuvanted formulations, particularly in older adults or immunocompromised populations.
Approved indications
- Influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients (PHASE2)
- Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59 (PHASE2)
- Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women (PHASE2)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults (PHASE1)
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inactivated adjuvanted Influenza Vaccine CI brief — competitive landscape report
- Inactivated adjuvanted Influenza Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Inactivated adjuvanted Influenza Vaccine
What is Inactivated adjuvanted Influenza Vaccine?
How does Inactivated adjuvanted Influenza Vaccine work?
What is Inactivated adjuvanted Influenza Vaccine used for?
Who makes Inactivated adjuvanted Influenza Vaccine?
What drug class is Inactivated adjuvanted Influenza Vaccine in?
What development phase is Inactivated adjuvanted Influenza Vaccine in?
What are the side effects of Inactivated adjuvanted Influenza Vaccine?
Related
- Drug class: All Vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Influenza prevention in adults
- Compare: Inactivated adjuvanted Influenza Vaccine vs similar drugs
- Pricing: Inactivated adjuvanted Influenza Vaccine cost, discount & access